Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 20/20 | 0.51 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | STAT3 | P40763 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20985223 | 1.00 | TYK2 (0.51) | TYK2JAK1STAT3JAK2STAT1 | |
| SCHEMBL26534957 | 0.94 | TYK2 (0.47) | TYK2JAK2 | |
| SCHEMBL20985221 | 0.92 | TYK2 (0.53) | TYK2JAK1STAT3JAK2STAT1 | |
| SCHEMBL20985309 | 0.87 | TYK2 (0.54) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL30617387 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL30617380 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL30617385 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL20985262 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL20985260 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 | |
| Lomedeucitinib SCHEMBL31663504 | 0.86 | TYK2 (0.61) | TYK2JAK1STAT3JAK2STAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240002364-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | US | disclosed |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021462-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
| US-20210253554-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
| US-11787779-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
| US-20240002364-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
| US-12365667-B2 | Sulfone pyridine alkyl amide-substituted heteroaryl compounds | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
| US-20190152948-A1 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | TYK2, JAK3, JAK2 | TYK2 1/4885JAK1 4/4885STAT3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.